Loading...

Investors & Media

Media Contact: Tully Nicholas Tnicholas@denterlein.com 617-482-0042

Investors & Media / News Releases

News Releases

December 3, 2018 - Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH December 2, 2018 - Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH November 20, 2018 - Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer November 13, 2018 - Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results November 7, 2018 - Apellis Pharmaceuticals to Present at Upcoming Investor Conferences November 1, 2018 - Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting September 28, 2018 - Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference September 12, 2018 - Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy September 4, 2018 - Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy July 31, 2018 - Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results July 24, 2018 - Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy June 26, 2018 - Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™ June 26, 2018 - Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) June 19, 2018 - Apellis Pharmaceuticals to Host R&D Day on June 26, 2018 May 31, 2018 - Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference April 30, 2018 - Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results April 23, 2018 - Apellis Pharmaceuticals Announces Closing of Offering of Common Stock April 18, 2018 - Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock April 16, 2018 - Apellis Pharmaceuticals Announces Proposed Offering of Common Stock April 16, 2018 - Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab March 19, 2018 - Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results February 23, 2018 - Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences February 22, 2018 - Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy January 2, 2018 - Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference